{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:39:10Z","timestamp":1792402750316,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00277-015-2501-1","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T23:37:41Z","timestamp":1443656261000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect of rituximab on adult Burkitt\u2019s lymphoma: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"95","author":[{"given":"Man","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Wen","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,1]]},"reference":[{"issue":"9822","key":"2501_CR1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","volume":"379","author":"EM Molyneux","year":"2012","unstructured":"Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S (2012) Burkitt\u2019s lymphoma. Lancet 379(9822):1234\u201344. doi: 10.1016\/S0140-6736(11)61177-X","journal-title":"Lancet"},{"key":"2501_CR2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B - cell lymphoma. N Engl J Med 346:235\u2013242. doi: 10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"2501_CR3","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","volume":"24","author":"T W\u00e4sterlid","year":"2013","unstructured":"W\u00e4sterlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D\u2019Amore F, Jerkeman M (2013) Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol 24:1879\u20131886. doi: 10.1093\/annonc\/mdt058","journal-title":"Ann Oncol"},{"issue":"1","key":"2501_CR4","first-page":"341","volume":"2008","author":"AS Perkins","year":"2008","unstructured":"Perkins AS, Friedberg JW (2008) Burkitt lymphoma in adults. ASH Educ Prog Book 2008(1):341\u2013348. doi: 10.1182\/asheducation-2008.1.341","journal-title":"ASH Educ Prog Book"},{"key":"2501_CR5","first-page":"91","volume":"1","author":"JA Rodrigo","year":"2012","unstructured":"Rodrigo JA, Hicks LK, Cheung MC, Song KW, Ezzat H, Leger CS, Boro J, Montaner JS, Harris M, Leitch HA (2012) HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M\/IVAC with or without Rituximab in the HAART Era. Adv Hematol 1:91\u20139. doi: 10.1155\/2012\/735392","journal-title":"Adv Hematol"},{"issue":"7","key":"2501_CR6","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","volume":"24","author":"T W\u00e4sterlid","year":"2013","unstructured":"W\u00e4sterlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D\u2019Amore F, Jerkeman M (2013) Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol 24(7):1879\u20131886. doi: 10.1093\/annonc\/mdt058","journal-title":"Ann Oncol"},{"issue":"1","key":"2501_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620713514682","volume":"5","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Farrington L, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, Fenske TS (2014) Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. Ther Adv Hematol 5(1):3\u201312. doi: 10.1177\/2040620713514682","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"2501_CR8","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS (2011) Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis. Ann Oncol 22(8):1859\u20131864. doi: 10.1093\/annonc\/mdq677","journal-title":"Ann Oncol"},{"key":"2501_CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000334705","volume":"127","author":"D Dujmovic","year":"2012","unstructured":"Dujmovic D, Aurer I, Radman I, Serventi-Seiwerth R, Dotlic S, Stern-Padovan R, Dubravcic K, Santek F, Labar B (2012) Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma\/leukemia. Acta Haematol Basel 127:115\u2013117. doi: 10.1159\/000334705","journal-title":"Acta Haematol Basel"},{"key":"2501_CR10","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u201312. doi: 10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"key":"2501_CR11","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ 339:b2700. doi: 10.1016\/j.jclinepi.2009.06.006","journal-title":"BMJ"},{"key":"2501_CR12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi: 10.1186\/1745-6215-8-16","journal-title":"Trials"},{"issue":"9193","key":"2501_CR13","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354(9193):1896\u2013900. doi: 10.1016\/S0140-6736(99)04149-5","journal-title":"Lancet"},{"key":"2501_CR14","unstructured":"Phillips B, Ball C, Sackett D (2009) Levels of evidence and grades of recommendation. Oxford Centre for Evidence-based Medicine Web site. http:\/\/www.cebm.net\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/ . Accessed March, 2009"},{"key":"2501_CR15","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"J Higgins","year":"2008","unstructured":"Higgins J, Green S (2008) Cochrane handbook for systematic reviews of interventions. John Wiley and Sons, New York"},{"key":"2501_CR16","unstructured":"GA Wells, B Shea, D O\u2019Connell, J Peterson, V Welch, M Losos, P Tugwell (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute Web site. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp . Accessed March 15, 2013"},{"key":"2501_CR17","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815\u201334. doi: 10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","journal-title":"Stat Med"},{"issue":"8","key":"2501_CR18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000000623","volume":"29","author":"F Alwan","year":"2015","unstructured":"Alwan F, He A, Montoto S, Kassam S, Mee M, Burns F, Edwards S, Wilson A, Tenant-Flowers M, Marcus R, Ardeshna KM, Bower M, Cwynarski K (2015) Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. AIDS 29(8):903\u2013910. doi: 10.1097\/QAD.0000000000000623","journal-title":"AIDS"},{"key":"2501_CR19","doi-asserted-by":"crossref","unstructured":"Ribrag V, Koscielny S, Bouabdallah K, Salles G, Casasnovas O, Recher C (2012) Addition of rituximab improves outcome of HIV negative patients with Burkitt lymphoma treated with the Lmba protocol: results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 protocol.(IGR sponsored LMBA02, NCT00180882). Blood 120(21), 685a","DOI":"10.1182\/blood.V120.21.685.685"},{"key":"2501_CR20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1182\/blood.V114.22.1667.1667","volume":"114","author":"JA Barnes","year":"2009","unstructured":"Barnes JA, LaCasce AS, Feng Y, Toomey C, Neuberg D, Hochberg EP, Abramson JS (2009) Rituximab added to CODOX-M\/IVAC has no clear benefit compared to CODOX-M\/IVAC alone in adult patients with Burkitt lymphoma. Blood 114:665\u2013666","journal-title":"Blood"},{"key":"2501_CR21","doi-asserted-by":"crossref","unstructured":"Carla Casulo, Jonathan Friedberg (2015) Treating Burkitt lymphoma in adults. Current hematologic malignancy reports 1-6. doi: 10.1007\/s11899-015-0263-4","DOI":"10.1007\/s11899-015-0263-4"},{"key":"2501_CR22","doi-asserted-by":"crossref","unstructured":"Kasamon Yvette L, Swinnen Lode J (2004) Treatment advances in adult Burkitt lymphoma and leukemia. Curr Opin Oncol 16(5):429\u2013435. doi: 10.1097\/00001622-200409000-00003","DOI":"10.1097\/00001622-200409000-00003"},{"key":"2501_CR23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","volume":"14","author":"I Magrath","year":"1996","unstructured":"Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925\u2013934","journal-title":"J Clin Oncol"},{"key":"2501_CR24","first-page":"33","volume":"25","author":"M Adde","year":"1998","unstructured":"Adde M, Shad A, Venzon D, Arndt C, Gootenberg J, Neely J, Nieder M, Owen W, Seibel N, Wilson W, Horak ID, Magrath I (1998) Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 25:33\u201339","journal-title":"Semin Oncol"},{"key":"2501_CR25","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","volume":"13","author":"GM Mead","year":"2002","unstructured":"Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, Guarnaccia C, Lewis MS, McKendrick J, Stenning SP, Wright D, UKLG\u2002LY06 collaborators (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 Group. Ann Oncol 13:1264\u20131274. doi: 10.1093\/annonc\/mdf253","journal-title":"Ann Oncol"},{"issue":"9","key":"2501_CR26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","volume":"15","author":"TF Tedder","year":"1994","unstructured":"Tedder TF, Engel P (1994) CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today 15(9):450\u2013454. doi: 10.1016\/0167-5699(94)90276-3","journal-title":"Immunol Today"},{"issue":"2","key":"2501_CR27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.msard.2013.08.001","volume":"3","author":"A Plate","year":"2014","unstructured":"Plate A, Havla J, K\u00fcmpfel T (2014) Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica. Multi Scler Relat Disord 3(2):269\u201372. doi: 10.1016\/j.msard.2013.08.001","journal-title":"Multi Scler Relat Disord"},{"key":"2501_CR28","unstructured":"Gross TG, Perkins SL (2011) Malignant non-Hodgkin lymphomas in children. Principles and practice of pediatric oncology. Lippincott Williams & Wilkins"},{"issue":"1","key":"2501_CR29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajh.22189","volume":"87","author":"G Todeschini","year":"2012","unstructured":"Todeschini G, Bonifacio M, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zam\u00f2 A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, Pizzolo G (2012) Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma\/leukemia. Am J Hematol 87(1):22\u20135. doi: 10.1002\/ajh.22189","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2501-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2501-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2501-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T01:59:04Z","timestamp":1599616744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2501-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2501"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2501-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,1]]}}}